How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…